News

GlobalData on MSN9h

Eli Lilly eyes orforglipron approval after Phase III diabetes trial success

Although data for Eli Lilly’s orforglipron may have disappointed investors earlier this month, a new release of Phase III ...

The bear case on Eli Lilly has played out, says only firm to have called it a sell

The bear case for Eli Lilly has now played out following the reaction to the drugmaker’s oral obesity drug trial, an analyst ...
Fierce Pharma6h

Facing pressure from Novartis, Eli Lilly trots out Verzenio patient survival win in early breast cancer

In the heat of the CDK4/6 market showdown, Eli Lilly has notched an overall survival win to back Verzenio’s case against ...

Stock Movers: Eli Lilly, EchoStar, UnitedHealth

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly says Verzenio extended survival in late-stage breast cancer trial

Eli Lilly (NYSE:LLY) announced on Wednesday that its FDA-approved antitumor agent Verzenio, as part of a combination regimen, ...

Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk)

The obesity-care market is largely dominated by just two players: Eli Lilly and Novo Nordisk. 10 stocks we like better than ...
Medical Marketing & Media1d

Why Eli Lilly is bullish on its oral GLP-1 after Phase 3 success

While existing GLP-1 medications have shown greater weight loss than Lilly’s oral medication, this option targets both weight loss and type 2 diabetes in patients.

Goldman Sachs Remains Positive as Eli Lilly (LLY) Expands Obesity Drug Pipeline

Reflecting this potential, Goldman Sachs analyst Asad Haider on August 15 reiterated a Buy rating on Eli Lilly and Company ...